SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Gut BarrierResearch peptide

Larazotide

aka AT-1001

Tight-junction regulator studied as an adjunct in celiac disease and intestinal permeability.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Larazotide is a synthetic octapeptide that acts on intestinal tight junctions to reduce paracellular permeability, mainly studied as an adjunct in celiac disease.

Source
  • Synthesized in research laboratories
Forms
  • Oral capsule

Mechanism of action

Antagonizes zonulin signaling at intestinal tight junctions, keeping them closed in response to gluten and other triggers.

Pathways
  • · Zonulin antagonism
  • · Tight-junction regulation (ZO-1, occludin)

How it acts on the body

Zonulin is the endogenous protein that signals intestinal tight junctions to open and close. In celiac disease and several other intestinal conditions, zonulin is overactive and tight junctions stay too open, allowing antigens to cross into the lamina propria and drive immune reactivity.

Larazotide is an antagonist that blocks zonulin-driven opening. Taken before meals, it reduces the post-gluten permeability and symptom flare in patients on a gluten-free diet who still react to trace exposure.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Zonulin signalingDecreases
Antagonism at tight junctions.
Inflammatory cytokinesDecreases
Downstream reduction from reduced antigen translocation.

Effects on the body

Supports
Intestinal barrier integrity
Decreases
Gluten-triggered symptom flares

Organ system effects

Digestive / Gut

Closes tight junctions in response to trigger antigens.

Immune System

Reduces antigen exposure to gut-associated lymphoid tissue.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Symptom reduction in celiac patients with persistent reactivity
  • Mechanism-targeted rather than symptomatic

Potential side effects

Common
  • · Headache
  • · Urinary tract symptoms
Rare
  • · Nausea
Serious
  • · No notable serious effects reported in trials

Drug interactions

No notable interactions reported.

Pairing context

Often combined with
  • Gluten-free diet adherence
    Adjunct, not replacement, for dietary control.
Avoid combining with
  • Active intestinal infection requiring barrier permeability for clearance
    Mechanism opposes that process.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.